Cytoreductive therapy is not routinely recommended for younger patients with polycythemia vera (PV) due to concern that treatment toxicity may outweigh therapeutic benefits. However, no systematic data supports this approach. To support objective risk/benefit assessment of cytoreductive drugs in PV patients younger than 60 (PV<60), this systematic review and meta-analysis was conducted to evaluate toxicity and disease-related complications in PV<60 treated with interferon alfa (rIFNα) or hydroxyurea (HU). A search of PubMed, Scopus, Web of Science and Embase identified 693 unique studies with relevant keywords, of which 14 met inclusion criteria and were selected for analysis. The weighted average age of patients treated with rIFNα was 48 years (n=744 patients, 12 studies) and for HU was 56 years (n=1397, 8 studies). The weighted average duration of treatment for either drug was 4.5 years. Using a Bayesian hierarchical model, the pooled annual rate of discontinuation due to toxicity was 5.2% (n=587, CI 2.2%-8.2%) for patients receiving rIFNα, and 3.6% (n=1097, CI 1%-6.2%) for HU. The average complete hematologic response (CHR) for rIFNα and HU was 62% and 52%, respectively. Patients experienced thrombotic events at a pooled annual rate of 0.79% and 1.26%; sMF at 1.06% and 1.62%; AML at 0.14% and 0.26%; and death at 0.87% and 2.65%, respectively. No treatment-related deaths were reported. With acceptable rates of non-fatal toxicity, cytoreductive treatment, particularly with disease-modifying rIFNα, may benefit PV<60. Future randomized trials prioritizing inclusion of PV<60 are needed to establish a long-term benefit of early cytoreductive treatment in these patients.
Skip Nav Destination
Review Article|
March 20, 2024
Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes
Reem S Chamseddine,
Reem S Chamseddine
Weill Cornell Medicine - Qatar, Doha, Qatar
Search for other works by this author on:
Oleksandr Savenkov,
Oleksandr Savenkov
Weill Cornell Medicine, New York, New York, United States
Search for other works by this author on:
Shehroz Tariq Rana,
Shehroz Tariq Rana
Weill Cornell Medicine - Qatar, Doha, Qatar
Search for other works by this author on:
Mohammed Khalid, Mr.,
Mohammed Khalid, Mr.
Weill Cornell Medicine - Qatar, Doha, Qatar
Search for other works by this author on:
Richard T. Silver,
Richard T. Silver
Weill Cornell Medicine, New York, New York, United States
Search for other works by this author on:
Nicole Kucine,
Nicole Kucine
Weill Cornell Medicine, New York, New York, United States
Search for other works by this author on:
Joseph Michael Scandura,
Joseph Michael Scandura
Weill-Cornell Medicine, New York, New York, United States
Search for other works by this author on:
Ghaith Abu-Zeinah
Weill Cornell Medicine, New York, New York, United States
* Corresponding Author; email: gfa2001@med.cornell.edu
Search for other works by this author on:
Blood Adv bloodadvances.2023012459.
Article history
Submitted:
December 19, 2023
Revision Received:
February 9, 2024
Accepted:
February 21, 2024
Citation
Reem S Chamseddine, Oleksandr Savenkov, Shehroz Tariq Rana, Mohammed Khalid, Richard T. Silver, Nicole Kucine, Joseph Michael Scandura, Ghaith Abu-Zeinah; Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes. Blood Adv 2024; bloodadvances.2023012459. doi: https://doi.org/10.1182/bloodadvances.2023012459
Download citation file:
Advertisement
Cited By
Advertisement